Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Sockel

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
The Lancet. Haematology|August 1, 2020
Treating myelodysplastic syndromes by nuclear transport inhibitionKatja Sockel
Drugs|November 24, 2018
Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?Katja Sockel, Uwe Platzbecker
Current Hematologic Malignancy Reports|October 5, 2013
When to transplant MDS, and what to do when transplant failsKatja Sockel, Uwe Platzbecker
The New England Journal of Medicine|December 22, 2018
Parvovirus B19 InfectionMarika Mende, Katja Sockel
Chinese Clinical Oncology|April 6, 2015
Is it already time for combination treatment in lower risk MDS?Katja Sockel, Uwe Platzbecker
British Journal of Haematology|August 26, 2025
Back to life: Biological parenthood of young adult acute leukaemia survivorsKatharina Egger-Heidrich, Katja Sockel, Johannes Schetelig
Frontiers in Immunology|February 21, 2022
Established and Emerging Treatments of Skin GvHDCornelia S Link-Rachner, Katja Sockel, Catharina Schuetz
Expert Review of Hematology|November 15, 2011
Optimizing management of myelodysplastic syndromes post-allogeneic transplantationKatja Sockel, Gerhard Ehninger, Lorenz C Hofbauer, et al.
International Journal of Molecular Sciences|October 23, 2021
Myelodysplastic Syndromes and MetabolismEkaterina Balaian, Manja Wobus, Martin Bornhäuser, et al.
Annals of Hematology|August 13, 2013
Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrowJudith Neukirchen, Uwe Platzbecker, Katja Sockel, et al.
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
The Lancet. Haematology|August 1, 2020
Treating myelodysplastic syndromes by nuclear transport inhibitionKatja Sockel
Drugs|November 24, 2018
Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?Katja Sockel, Uwe Platzbecker
Current Hematologic Malignancy Reports|October 5, 2013
When to transplant MDS, and what to do when transplant failsKatja Sockel, Uwe Platzbecker
The New England Journal of Medicine|December 22, 2018
Parvovirus B19 InfectionMarika Mende, Katja Sockel
Chinese Clinical Oncology|April 6, 2015
Is it already time for combination treatment in lower risk MDS?Katja Sockel, Uwe Platzbecker
British Journal of Haematology|August 26, 2025
Back to life: Biological parenthood of young adult acute leukaemia survivorsKatharina Egger-Heidrich, Katja Sockel, Johannes Schetelig
Frontiers in Immunology|February 21, 2022
Established and Emerging Treatments of Skin GvHDCornelia S Link-Rachner, Katja Sockel, Catharina Schuetz
Expert Review of Hematology|November 15, 2011
Optimizing management of myelodysplastic syndromes post-allogeneic transplantationKatja Sockel, Gerhard Ehninger, Lorenz C Hofbauer, et al.
International Journal of Molecular Sciences|October 23, 2021
Myelodysplastic Syndromes and MetabolismEkaterina Balaian, Manja Wobus, Martin Bornhäuser, et al.
Annals of Hematology|August 13, 2013
Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrowJudith Neukirchen, Uwe Platzbecker, Katja Sockel, et al.
Pageof 10